KRAS and familial pancreatic carcinoma: Heterogeneous genomic alterations in pancreatic cancer comprising numerous mutations of tumour suppressor genes (inter alia KRAS, CDKN2A, CDK4, TP53, STK11, ATM, MLH1, MSH2, MSH6, PALB2, SMAD4/DPC4, BRCA1, and BRCA2), and their role in PDAC carcinogenesis and progression have been broadly investigated and described [6,8,9].